| 1 |
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 579(7798):270-273.
|
| 2 |
Sachs JD, Karim SSA, Aknin L, et al. The Lancet Commission on lessons for the future from the COVID-19 pandemic[J]. Lancet, 2022, 400(10359):1224-1280.
|
| 3 |
Kow CS, Ramachandram DS, Hasan SS. The risk of mortality and severe illness in patients infected with the omicron variant relative to delta variant of SARS-CoV-2: a systematic review and meta-analysis[J]. Ir J Med Sci, 2023, 1-8.
|
| 4 |
Wilkinson SAJ, Richter A, Casey A, et al. Recurrent SARS-CoV-2 mutations in immunodeficient patients[J]. Virus Evol, 2022, 8(2):veac050.doi: 10.1093/ve/veac050.
|
| 5 |
Abouir K, Gosselin P, Guerrier S, et al. Dexamethasone exposure in normal-weight and obese hospitalized COVID-19 patients: An observational exploratory trial[J]. Clin Transl Sci, 2022, 15(7):1796-1804.
|
| 6 |
Rachina S, Belkova Y, Shchendrygina A, et al. Safety and efficacy of different anticoagulant doses for patients with COVID-19 in the ICU: a systematic review and meta-analysis[J]. J Clin Med, 2023, 12(6):2222.doi: 10.3390/jcm12062222.
|
| 7 |
Zhang Y, Li J, Yang M, et al. Effect of vitamin D supplementation on COVID-19 patients: a systematic review and meta-analysis[J]. Front Nutr, 2023, 10:1131103.doi: 10.3389/fnut.2023.1131103.
|
| 8 |
Inchingolo AD, Dipalma G, Inchingolo AM, et al. The 15-months clinical experience of SARS-CoV-2: a literature review of therapies and adjuvants[J]. Antioxidants (Basel), 2021, 10(6):881.doi: 10.3390/antiox10060881.
|
| 9 |
Nichol AD, O'Kane C, McAuley DF. Respiratory support in the time of COVID-19[J]. JAMA, 2022, 328(12):1203-1205.
|
| 10 |
Khoury J, Najjar-Debbiny R, Hanna A, et al. COVID-19 vaccine- Long term immune decline and breakthrough infections[J]. Vaccine, 2021, 39(48):6984-6989.
|
| 11 |
Chu M, Wang H, Bian L, et al. Nebulization therapy with umbilical cord mesenchymal stem cell-derived exosomes for COVID-19 pneumonia[J]. Stem cell Rev Rep, 2022, 18(6):2152-2163.
|
| 12 |
Meng F, Xu R, Wang S, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial[J]. Signal Transduct Target Ther, 2020, 5(1):172.doi: 10.1038/s41392-020-00286-5.
|
| 13 |
Shi L, Huang H, Lu X, et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial[J]. Signal Transduct Target Ther, 2021, 6(1):58.doi: 10.1038/s41392-021-00488-5.
|
| 14 |
Shi L, Yuan X, Yao W, et al. Human mesenchymal stem cells treatment for severe COVID-19:1-year follow-up results of a randomized, double-blind, placebo-controlled trial[J]. EBioMedicine, 2022, 75:103789.doi: 10.1016/j.ebiom.2021.103789.
|
| 15 |
Shu L, Niu C, Li R, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells[J]. Stem Cell Res Ther, 2020, 11(1):361.doi: 10.1186/s13287-020-01875-5.
|
| 16 |
Xu X, Jiang W, Chen L, et al. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial[J]. Clin Transl Med, 2021, 11(2):e297.doi: 10.1002/ctm2.297.
|
| 17 |
Zhu YG, Shi MM, Monsel A, et al. Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study[J]. Stem Cell Res Ther, 2022, 13(1):220.doi: 10.1186/s13287-022-02900-5.
|
| 18 |
Adas G, Cukurova Z, Yasar KK, et al. The Systematic effect of mesenchymal stem cell therapy in critical COVID-19 patients: a prospective double controlled trial[J]. Cell Transplant, 2021, 30:9636897211024942.doi: 10.1177/09636897211024942.
|
| 19 |
Aghayan HR, Salimian F, Abedini A, et al. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment[J]. Stem Cell Res Ther, 2022, 13(1):365.doi: 10.1186/s13287-022-02953-6.
|
| 20 |
Bowdish ME, Barkauskas CE, Overbey JR, et al. A randomized trial of mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome from COVID-19[J]. Am J Respir Crit Care Med, 2023, 207(3):261-270.
|
| 21 |
Fathi-Kazerooni M, Fattah-Ghazi S, Darzi M, et al. Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II[J]. Stem Cell Res Ther, 2022, 13(1):96.doi: 10.1186/s13287-022-02771-w.
|
| 22 |
Kaffash Farkhad N, Sedaghat A, Reihani H, et al. Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial[J]. Stem Cell Res Ther, 2022, 13(1):283.doi: 10.1186/s13287-022-02920-1.
|
| 23 |
Karyana M, Djaharuddin I, Rif'ati L, et al. Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial[J]. Stem Cell Res Ther, 2022, 13(1):134.doi: 10.1186/s13287-022-02812-4.
|
| 24 |
间充质干细胞治疗新型冠状病毒肺炎专家共识（2021年，北京）[J]. 传染病信息, 2021, 34(2):99-106.
|
| 25 |
Najar M, Raicevic G, Fayyad-Kazan H, et al. Immune-related antigens, surface molecules and regulatory factors in human-derived mesenchymal stromal cells: the expression and impact of inflammatory priming[J]. Stem Cell Rev Rep, 2012, 8(4):1188-1198.
|
| 26 |
Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed Coronavirus Disease 2019-COVID-NET, 14 States, March 1-30, 2020[J]. MMWR Morb Mortal Wkly Rep, 2020, 69(15):458-464.
|
| 27 |
Peña JE, Rascón-Pacheco RA, Ascencio-Montiel IJ, et al. Hypertension, diabetes and obesity, major risk factors for death in patients with COVID-19 in Mexico[J]. Arch Med Res, 2021, 52(4):443-449.
|
| 28 |
Rebelatto CLK, Senegaglia AC, Franck CL, et al. Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial[J]. Stem Cell Res Ther, 2022, 13(1):122.doi: 10.1186/s13287-022-02796-1.
|
| 29 |
Kouroupis D, Lanzoni G, Linetsky E, et al. Umbilical cord-derived mesenchymal stem cells modulate TNF and soluble TNF Receptor 2 (sTNFR2) in COVID-19 ARDS patients[J]. Eur Rev Med Pharmacol Sci, 2021, 25(12):4435-4438.
|
| 30 |
Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically Ill patients With COVID-19: a meta-analysis[J]. Jama, 2020, 324(13):1330-1341.
|
| 31 |
Monsel A, Hauw-Berlemont C, Mebarki M, et al. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial[J]. Crit Care, 2022, 26(1):48.doi: 10.1186/s13054-022-03930-4.
|
| 32 |
Lanzoni G, Linetsky E, Correa D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial[J]. Stem Cells Transl Med, 2021, 10(5):660-673.
|
| 33 |
Saleh M, Vaezi AA, Aliannejad R, et al. Cell therapy in patients with COVID-19 using Wharton's jelly mesenchymal stem cells: a phase 1 clinical trial[J]. Stem Cell Res Ther, 2021, 12(1):410.doi: 10.1186/s13287-021-02483-7.
|
| 34 |
Gan Y, Zhang T, Chen X, et al. Steroids enable mesenchymal stromal cells to promote CD8(+) T cell proliferation Via VEGF-C[J]. Adv Sci (Weinh), 2021, 8(12):2003712.doi: 10.1002/advs.202003712.
|
| 35 |
Chen L, Qu J, Kalyani FS, et al. Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications[J]. Cell Mol Life Sci, 2022, 79(3):142.doi: 10.1007/s00018-021-04096-y.
|
| 36 |
N OE, Pekkoc-Uyanik KC, Alpaydin N, et al. Clinical experience on umbilical cord mesenchymal stem cell treatment in 210 severe and critical COVID-19 cases in Turkey[J]. Stem cell Rev Rep, 2021, 17(5):1917-1925.
|
| 37 |
Sadeghi B, Roshandel E, Pirsalehi A, et al. Conquering the cytokine storm in COVID-19-induced ARDS using placenta-derived decidua stromal cells[J]. J Cell Mol Med, 2021, 25(22):10554-10564.
|
| 38 |
Hashemian SR, Aliannejad R, Zarrabi M, et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series[J]. Stem Cell Res Ther, 2021, 12(1):91.doi: 10.1186/s13287-021-02165-4.
|
| 39 |
Grégoire C, Layios N, Lambermont B, et al. Bone marrow-derived mesenchymal stromal cell therapy in severe COVID-19: preliminary results of a phase I/II clinical trial[J]. Front Immunol, 2022, 13：932360.doi: 10.3389/fimmu.2022.932360.
|
| 40 |
Dilogo IH, Aditianingsih D, Sugiarto A, et al. Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: a randomized controlled trial[J]. Stem Cells Transl Med, 2021, 10(9):1279-1287.
|
| 41 |
Zhang Z, Shao S, Liu X, et al. Effect and safety of mesenchymal stem cells for patients with COVID-19: systematic review and meta-analysis with trial sequential analysis[J]. J Med Virol, 2023, 95(4):e28702.doi: 10.1002/jmv.28702.
|
| 42 |
Rebelatto CLK, Senegaglia AC, Franck CL, et al. Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial[J]. Stem Cell Res Ther, 2022, 13(1):122.doi: 10.1186/s13287-022-02796-1.
|
| 43 |
Sengupta V, Sengupta S, Lazo A, et al. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19[J]. Stem Cells Dev, 2020, 29(12):747-754.
|
| 44 |
Lanzoni G, Linetsky E, Correa D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial[J]. Stem Cells Transl Med, 2021, 10(5):660-673.
|
| 45 |
Saengsiwaritt W, Jittikoon J, Chaikledkaew U, et al. Genetic polymorphisms of ACE1, ACE2, and TMPRSS2 associated with COVID-19 severity: A systematic review with meta-analysis[J]. Rev Med Virol, 2022, 32(4):e2323.doi: 10.1002/rmv.2323.
|
| 46 |
Zhang HP, Sun YL, Wang YF, et al. Recent developments in the immunopathology of COVID-19[J]. Allergy, 2023, 78(2):369-388.
|
| 47 |
Weiss ARR, Dahlke MH. Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs[J]. Front Immunol, 2019, 10:1191.doi: 10.3389/fimmu.2019.01191.
|
| 48 |
Du YM, Zhuansun YX, Chen R, et al. Mesenchymal stem cell exosomes promote immunosuppression of regulatory T cells in asthma[J]. Exp Cell Res, 2018, 363(1):114-120.
|
| 49 |
Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential[J]. Trends Pharmacol Sci, 2020, 41(9):653-664.
|
| 50 |
Lu K, Geng ST, Tang S, et al. Clinical efficacy and mechanism of mesenchymal stromal cells in treatment of COVID-19[J]. Stem Cell Res Ther, 2022, 13(1):61.doi: 10.1186/s13287-022-02743-0.
|
| 51 |
Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases[J]. Nat Rev Nephrol, 2018, 14(8): 493-507.
|
| 52 |
Lopez-Garcia L, Castro-Manrreza ME. TNF-alpha and IFN-gamma participate in improving the immunoregulatory capacity of mesenchymal stem/stromal cells: importance of cell-cell contact and extracellular vesicles[J]. Int J Mol Sci, 2021, 22(17):9531. doi: 10.3390/ijms22179531.
|
| 53 |
Luz-Crawford P, Djouad F, Toupet K, et al. Mesenchymal stem cell-derived interleukin 1 Receptor antagonist promotes macrophage polarization and inhibits B cell differentiation[J]. Stem Cells, 2016, 34(2):483-492.
|
| 54 |
Schmidt A, Zhang XM, Joshi RN, et al. Human macrophages induce CD4(+)Foxp3(+) regulatory T cells via binding and re-release of TGF-beta[J]. Immunol Cell Biol, 2016, 94(8):747-762.
|
| 55 |
Lee S, Jung S, Kim HJ, et al. Mesenchymal stem cell-derived extracellular vesicles subvert Th17 cells by destabilizing RORgammat through posttranslational modification[J]. Exp Mol Med, 2023, 55(3):665-679.
|
| 56 |
Franquesa M, Mensah FK, Huizinga R, et al. Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells[J]. Stem Cells, 2015, 33(3):880-891.
|
| 57 |
Han Y, Li X, Zhang Y, et al. Mesenchymal stem cells for regenerative medicine[J]. Cells, 2019, 8(8):886.doi: 10.3390/cells8080886.
|
| 58 |
Harrell CR, Sadikot R, Pascual J, et al. Mesenchymal stem cell-based therapy of inflammatory lung diseases: current understanding and future perspectives[J]. Stem Cells Int, 2019, 2019:4236973.doi: 10.1155/2019/4236973.
|
| 59 |
Sadeghi S, Soudi S, Shafiee A, et al. Mesenchymal stem cell therapies for COVID-19: current status and mechanism of action[J]. Life Sci, 2020, 262:118493.doi: 10.1016/j.lfs.2020.118493.
|
| 60 |
Shafiee A, Patel J, Lee JS, et al. Mesenchymal stem/stromal cells enhance engraftment, vasculogenic and pro-angiogenic activities of endothelial colony forming cells in immunocompetent hosts[J]. Sci Rep, 2017, 7(1):13558.doi: 10.1038/s41598-017-13971-3.
|
| 61 |
Wick KD, Leligdowicz A, Zhuo H, et al. Mesenchymal stromal cells reduce evidence of lung injury in patients with ARDS[J]. JCI insight, 2021, 6(12):e148983.doi: 10.1172/jci.insight.148983.
|
| 62 |
Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia[J]. Aging Dis, 2020, 11(2):216-228.
|
| 63 |
Zarrabi M, Shahrbaf MA, Nouri M, et al. Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial[J]. Stem Cell Res Ther, 2023, 14(1):169.doi: 10.1186/s13287-023-03402-8.
|